Exosomes in HPV-Associated Cancers: From Biomarkers to Engineered Therapeutics
Cancers · 21.10.2025 · 17 (20) · 3386
DOI: 10.3390/cancers17203386 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.10.2025. Verfasst von Muharrem Okan Cakir und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Pharmacy and Chemistry, Kingston University London, London KT1 2EE, UK. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Human papillomavirus (HPV) is the main causative agent of cervical cancer and contributes to a significant proportion of other anogenital and oropharyngeal malignancies. The need for better biomarkers and therapeutic approaches in HPV-associated cancers has drawn attention to exosomes, small extracellular vesicles known for their stability, biomolecule transport capabilities, and role in cell-to-cell communication.
Methods
This review comprehensively evaluates recent literature on the diagnostic, prognostic, and therapeutic applications of small extracellular vesicles, particularly exosomes, in HPV-related cancers. It analyzes findings on exosomal nucleic acids, proteins, and long non-coding RNAs, as well as engineered exosome-based therapies.
Results
Exosomal miRNAs (e.g., miR-204-5p, miR-99a-5p, miR-21), proteins (e.g., glycolytic enzymes, HSP90), and lncRNAs (e.g., HOTAIR, DLEU1) have emerged as promising biomarkers for disease detection and monitoring. Exosomal cargo actively participates in HPV-related tumor progression. For example, miRNAs such as miR-21 and miR-146a modulate immune cell polarization and inflammatory signaling, while lncRNAs like HOTAIR promote oncogenic transcriptional programs. Exosomal proteins including HSP90 and ANXA1 facilitate extracellular matrix remodeling and immune evasion, thereby influencing tumor growth and metastasis. In HPV-positive head and neck and cervical cancers, exosomal cargo reflects HPV status, tumor progression, and treatment response. Therapeutic studies demonstrate the utility of exosomes in vaccine delivery, immune modulation, and drug delivery systems, including the use of PROTACs. However, clinical translation faces barriers including isolation protocol standardization, biomarker validation, and scalable production.
Conclusions
Exosomes hold great promise for integration into diagnostic and therapeutic workflows for HPV-related cancers. Future research should focus on resolving standardization issues, validating biomarkers in diverse cohorts, and optimizing engineered exosome platforms for targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences, Pharmacy and Chemistry, Kingston University London, London KT1 2EE, UK.
- School of Medicine, Koc University, Sarıyer, Istanbul 34450, Turkey.
- Department of Biochemistry, School of Medicine & Genetic and Metabolic Disease Research and Investigation Center, Marmara University, Istanbul 34854, Turkey.
- Department of Biochemistry, School of Medicine, Recep Tayyip Erdogan University, Rize 53100, Turkey.
- Division of Medical Oncology, Memorial Hospital, Antalya 07050, Turkey.
ORCID-Profile: Muharrem Okan Cakir, Melis Selek, Betul Yilmaz, G Hossein Ashrafi
Zitieren
APA
Cakir, M. O., Selek, M., Yilmaz, B., Ozdogan, M., & Ashrafi, G. H. (2025). Exosomes in HPV-Associated Cancers: From Biomarkers to Engineered Therapeutics. Cancers, 17(20), 3386. https://doi.org/10.3390/cancers17203386
Vancouver
Cakir MO, Selek M, Yilmaz B, Ozdogan M, Ashrafi GH. Exosomes in HPV-Associated Cancers: From Biomarkers to Engineered Therapeutics. Cancers. 2025;17(20):3386. doi:10.3390/cancers17203386
BibTeX
@article{Cakir2025,
author = {Cakir, Muharrem Okan and Selek, Melis and Yilmaz, Betul and Ozdogan, Mustafa and Ashrafi, G Hossein},
title = {Exosomes in HPV-Associated Cancers: From Biomarkers to Engineered Therapeutics},
journal = {Cancers},
year = {2025},
volume = {17},
number = {20},
pages = {3386},
doi = {10.3390/cancers17203386}
}
EUVIMED